
AMD
Latest News
Latest Videos

Shorts





CME Content
More News

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.

The latest in drug and technology developments and updates from August 2026.

Phase 3 Duravyu insert misses key vision end point in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

Catch up on the top stories in optometry during the week of August 10-14.

Hamza Shah, OD, MS, FAAO, and Carolyn Majcher, OD, FAAO, weigh in on the recent FDA approval of the drug, which has been used off-label by compounding pharmacies for nearly 2 decades.

Physicians recommend a Mediterranean or similar diet to slow the progression of age-related macular degeneration, the leading cause of irreversible vision loss in older adults.

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

The study, conducted through the OHDSI network, analyzed records from 227,971 new users of semaglutide.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

AMD affects approximately 28 million people in the US and is a leading cause of vision loss among older adults.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

The study, published in PLoS Genetics, examined how glucose metabolism affects gene expression in light-sensing photoreceptors.

Researchers noted growing evidence supporting an additional role for B vitamins.

The analysis included 12,183,254 patients, with 304,823 identified as smokers and 11,878,431 as non-smokers.

Phase 2 ArMaDa data show statistically significant 31% reduction in geographic atrophy lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).





















